^
Association details:
Biomarker:BRAF wild-type
Cancer:Colorectal Cancer
Drug:SCT200 (EGFR antagonist)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

Safety and Efficacy of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Wild-type RAS and BRAF mCRC

Excerpt:
...RAS and BRAF wildtype status of primary colorectal cancer or related metastasis; 8....
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Safety, pharmacokinetics and efficacy of SCT200, an anti-EGFR monoclonal antibody in patients with wild-type KRAS/NRAS/BRAF metastatic colorectal cancer: a phase I dose-escalation and dose-expansion study

Published date:
10/28/2022
Excerpt:
The objective response rate (ORR) was 30.4% (17/56, 95% confidence interval [CI], 18.8%-44.1%). The ORR in the dose-expansion group (6.0 mg/kg QW) was 48.0% (12/25, 95% CI, 27.8%-68.7%), the median progression-free survival was 5.2 months (95%CI, 3.6-5.5), and the median overall survival was 20.2 months...SCT200 showed favorable safety, PK profile, and preliminary efficacy for patients with wild-type KRAS/NRAS/BRAF mCRC.
DOI:
10.1186/s12885-022-10147-9